Your gateway to insightful market trends, prudent personal finance advice, and the pulse of global economy.

admin@smartmoneywins.com

USA Finance Digest is your one-stop destination for the latest financial news and insights

Popular
Your gateway to insightful market trends, prudent personal finance advice, and the pulse of global economy.



Key Points
Moderna has a dominant grasp on the Covid vaccine market — and a significant revenue contributor for years to come.
Moderna’s second commercialized product is expected to be the RSV vaccine MRNA-1345, a catalyst Moderna shareholders have long awaited.
Oppenheimer analyst Hartaj Singh kicked off the new year by upgrading MRNA to a Buy.
5 stocks we like better than Moderna
  Upgrade NowThis premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.Already have an account? Log in here.Before you consider Moderna, you’ll want to hear this.MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Moderna wasn’t on the list.While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising. Get This Free Report

Share this article
Shareable URL
Prev Post
Next Post
Leave a Reply

Your email address will not be published. Required fields are marked *

Read next
Key Points Palantir stock opened trading on March 6, 2024, at just over $26 a share. It’s the highest the…
Key Points Oracle had a weaker-than-expected quarter, but the top-line miss is slim, and margins are impressive.…
Key Points The energy sector faces a risk-off scenario in 2024, grappling with underperformance amid market…